Background With better understanding of the disease's etiology and mechanism, many targeted agents are being developed to tackle the root cause of problems, hoping to offer more effective and less toxic therapies. Targeted agents, however, do not work for everyone. Hence, the development of target agents requires the evaluation of prognostic and predictive markers. In addition, upon the identification of each patient's marker profile, it is desirable to treat patients with best available treatments in the clinical trial accordingly. Methods Many designs have recently been proposed for the development of targeted agents. These include the simple randomization design, marker stratified design, marker strategy design, efficient targeted design, etc. In contrast to the frequentist designs with equal randomization, we propose novel Bayesian adaptive randomization designs that allow evaluating treatments and markers simultaneously, while providing more patients with effective treatments according to the patients' marker profiles. Early stopping rules can be implemented to increase the efficiency of the designs. Results Through simulations, the operating characteristics of different designs are compared and contrasted. By carefully choosing the design parameters, types I and II errors can be controlled for Bayesian designs. By incorporating adaptive randomization and early stopping rules, the proposed designs incorporate rational learning from the interim data to make informed decisions. Bayesian design also provides a formal way to incorporate relevant prior information. Compared with previously published designs, the proposed design can be more efficient, more ethical, and is also more flexible in the study conduct. Limitations Response adaptive randomization requires the response to be assessed in a relatively short time period. The infrastructure must be set up to allow timely and more frequent monitoring of interim results. Conclusion Bayesian adaptive randomization designs are distinctively suitable for the development of multiple targeted agents with multiple biomarkers. Clinical Trials
Introduction
With better understanding of the disease causing mechanisms, many targeted agents are being developed recently to tackle the root cause problem of the disease with the hope to offer more effective and less toxic therapies. For example, cytotoxic chemotherapy has been used in treating cancer for over 50 years. Many cytotoxic agents take effects by impairing mitosis and are more effective for fastdividing cells such as cancer. However, as a result, fast-dividing normal cells are also being killed indiscriminately, which results in substantial toxicity. Targeted agents, on the other hand, have specific 'targets' that the drugs attack [1] . For example, imatinib is highly effective in chronic myelogenous leukemia (CML) because CML is fueled by the bcr-abl protein and imatinib inhibits it [2] . Trastuzumab works well in a subset of breast cancer patients presented with HER-2 [3] . The development of target agents requires the evaluation of the corresponding markers for their use in predicting the treatment efficacy and/or toxicity. In addition, it is desirable to identify each patient's marker profile in order to provide the best available treatments accordingly [4, 5] .
Thanks to the knowledge explosion in this genomic era, many disease-causing mechanisms and the corresponding drugable targets are identified. Pharmaceutical companies and research institutions are engaged in screening thousands and thousands of compounds or combinations to identify potentially effective ones [6] . It poses a huge challenge to test numerous putative agents with only limited patient resources [7] . The co-development of the associated markers is equally challenging. Key questions to be investigated include the following: Does the treatment work for all patients or only in a subset of patients with certain marker profiles? Are there markers available which can help us to evaluate the treatment's efficacy and/or toxicity? In cases when the treatment only works in a small fraction of marker-positive patients, the overall treatment effect may be low and the drug could be abandoned. Furthermore, we often do not know what these markers are and accurate assays to measure them may not exist. The amount of resources it takes and the time pressure make the drug development even more difficult.
Another challenge faced by clinical trial practitioners is the competing interest between individual ethics and group ethics. Based on individual ethics, patients should be assigned to the best available treatment, and the total number of successes in the trial should be maximized. Because the best available treatment is yet to be defined during the study, the response-based adaptive randomization (AR) can be applied to enhance individual ethics [8] [9] [10] . On the other hand, according to group ethics, the statistical power of a trial should be maximized such that, after the trial, a better treatment is defined for the general population. This is typically accomplished by applying equal randomization (ER), in which the individual need of patients in the trial to receive the best available treatment is largely ignored. A good clinical trial design should strike a balance between individual ethics and group ethics [11, 12] .
In targeted agent development, we want to find out whether the treatment works or not. If the treatment does not work in all patients, does the treatment work in a subset of patients? Are there markers which can be used to identify such subsets? Can markers be measured accurately and timely? Can the trial be conducted in smaller number of patients and a decision can be reached earlier? Can we treat patients better during the trial based on patients' marker profile? In facing these voluminous challenges, how do we move forward? Traditional clinical trial designs are more rigid and can only answer a small number of well-formulated questions. How can we do better? We need a design that is accurate in decision making and inference drawing, efficient in requiring smaller number of patients or shorter trial duration, and ethical in that patients are treated with best available treatments during the trial. The design must be flexible in that it is amendable to change during its course. In short, we are looking for a smart design that can meet all these challenges. Because most of the facts are not known at the beginning of the trial, adaptive designs allow us to continue to learn and adapt during the trial [13] [14] [15] [16] .
We argue that Bayesian framework is particularly suitable for adaptive designs because the inference does not depend on a particular, preset sampling scheme. It allows frequent analyses and monitoring of the trial's interim data. It can incorporate prior information easily. Under a hierarchical model, it can 'borrow strength' across similar groups. Via simulations, one can choose the design parameters to obtain desirable frequentist properties, for example, controlling types I and II error rates [17] [18] [19] [20] [21] [22] [23] .
Many frequentist designs have been proposed recently for the development of target agents [24] [25] [26] . In contrast to the frequentist designs with ER, we propose novel Bayesian adaptive randomization (BAR) designs to allow evaluating the treatment and marker effect simultaneously while treating more patients with more effective treatments according to patients' biomarker profiles. Early stopping rules can be implemented to increase the efficiency of the designs. These designs will be studied in more details in the following sections.
BAR applied in designs with two treatments, no markers
To illustrate how response-based AR works under the Bayesian framework, we first study a simple case of testing the response rates between two treatments with no markers. Assume p i is the response rate, x i is the number of responders, and n i is the total number of patients for treatment i, i ¼ 1, 2. Based on the standard binomial distribution, we have X i $ binomial(n i , p i ). With a conjugate beta prior distribution for p i taken as f 0 (p i ) ¼ beta(a 0 , b 0 ), the posterior distribution of p i can be easily calculated as f(p i ) ¼ beta(a 0 þ x i , b 0 þ n i À x i ). A decision rule can be set to compare the response rate between the two treatments. For example, we conclude that treatment 1 is better than treatment treatment 1 if Pr(p 2 >p 1 )>0.975. Otherwise, we conclude that treatments 1 and 2 are not significantly different.
The standard study design is to equally randomize patients between the two treatments and compare the result at the end of study. The AR, on the other hand, assumes that patients are enrolled over time, and one can use the interim results to preferentially allocate more patients into the more effective treatment. There are many choices for the randomization ratio. For example, the probability of randomizing the next patient into treatment 1 can be chosen asp 1 =ðp 1 þp 2 Þ or Prð p 1 >p 2 Þ =ðPrð p 1 >p 2 Þ þ Prð p 2 >p 1 Þ Þ, wherep i is its posterior mean and is the tuning parameter. Note that when ¼ 0, it corresponds to ER. When ¼ 1, it becomes the 'play-the-winner' design, in which the next patient is assigned to the current winner treatment based on the available data and no randomization is involved. The larger the is, the more imbalance the randomization will be. Figure 1 shows the randomization probability and the observed response rate over time for five simulated trials in the setting, where p 1 ¼ 0.1, p 2 ¼ 0.3, and n ¼ 80. We also assume that patients are enrolled sequentially and the response status is known instantaneously. With ER, the randomization probabilities converge to 0.5 as the trial moves along (upper left panels). The observed response rates converge to 0.1 and 0.3 (their corresponding true values) for treatments 1 and 2, respectively (bottom left panels). The right panels show the performance of AR. With AR, we first equally randomize 20 patients and afterward adaptively randomize the next 60 patients. The AR probability to treatment 1 isp 1 =ðp 1 þp 2 Þ. After 20 patients, the randomization ratio decreases for treatment 1 and increases for treatment 2, depicting that more patients are randomized into the better treatment. The resulting observed response rates also converge to their corresponding true values as the trial continues. Table 1 shows the operating characteristics for four designs with 5000 simulation studies using the AR program developed at M. D. Anderson Cancer Center (http://biostatistics.mdanderson.org/ SoftwareDownload/). The four designs are (1) ER with N ¼ 200 without early stopping, (2) AR with N ¼ 200 without early stopping, (3) AR with N max ¼ 200 and early stopping, and (4) AR with N max ¼ 250 and early stopping. We evaluate the treatment effect by comparing the posterior distribution of the probability of response, for example, treatment 1 is claimed to be better if Pr(p 1 >p 2 )>, where is a cutoff of the probability treatment 1 being better than treatment 2. An early stopping rule is implemented using a cutoff of 0.999, and at the end of study, a cutoff of 0.975 is used to make inference of the treatment efficacy. The performance of each method under the null hypothesis of p 1 ¼ p 2 ¼ 0.3 and the alternative hypothesis of p 1 ¼ 0.3, p 2 ¼ 0.5 are studied. Without early stopping, ER yields 5% type I error rate and 83% power under the null and alternative hypotheses, respectively. With AR, the type I error rate is slightly higher (8%), and the power is a bit lower (75%) due to the imbalance of treatment assignment. Under H 1 , the averaged numbers of patients randomized into treatments 1 and 2 are 46 and 154, respectively. The result illustrates the trade-off between individual ethics and group ethics. AR enhances the individual ethics by assigning 77% of patients to the better treatment comparing to 50% by ER. However, due to imbalance in treatment allocation, the power is reduced from 83% to 75%.
One way to increase the study efficiency is to incorporate early stopping rules. Based on the interim result, if there is convincing evidence that one treatment is better than another, there is no need to continue the study. One can stop the trial early and announce the study result. Therefore, early stopping not only saves the sample size but can also allow better treatment to be adopted earlier in the general population. With AR and early stopping, the type I error rate rises again slightly to 10%, and there is a 4% chance of stopping the trial early under the null hypothesis. Under the alternative hypothesis, 34% of the time the trial will be stopped early. The averaged sample size is reduced from 200 to 167. The power and proportion of patients assigned to treatment 2 are comparable to AR without early stopping. To remedy the lower power resulting from imbalance due to AR, one can increase the maximum sample size. When the maximum sample size is increased to 250, the power is raised to 85%. The expected sample size is 196 with 77% of the patients receiving better treatment. Comparing to ER, the averaged number of patients treated in the trial is comparable. However, under the alternative hypothesis, AR with early stopping can result in both higher power and treating more patients with effective treatment, that is, getting the best from both worlds. We can also add early futility stopping rules to further reduce the expected sample size under the null hypothesis.
BAR and Frequentist's designs applied in designs with two treatments, one marker
In the targeted agent development, putative markers play a role in guiding the selection of treatment. By convention, markers can be broadly classified as prognostic or predictive. A prognostic marker is a marker that is associated with the patient's disease outcome regardless of treatment or in patients receiving standard care. For example, early-stage patients tend to do better than late-stage patients in cancer no matter what treatment is given. Patients with good performance status are 
likely to do better than patients with poor performance status, and so on. In contrast, a predictive marker for a treatment is a marker that can predict the treatment outcome based on the marker status. For example, it is well established that lung cancer patients with EGFR mutation tend to do better than patients without mutation if they are given tyrosine kinase inhibitor such as gefitinib or erlotinib. The treatment does not work well in patients without mutation because they do not have the 'target' for the targeted agent to work on [27] .
In the case with two treatments, one binary marker with a binary outcome, we illustrate that the BAR can be applied to achieve the following three goals: (1) test whether the marker is prognostic or predictive, (2) test whether the new treatment works better than the standard treatment in all patients or in patients within certain marker subsets, and (3) treat patients better in the trial by assigning more patients to the more effective treatment based on the patients' marker status. Most of the standard frequentist designs can also achieve the first two goals. Table 2 depicts five illustrative scenarios. Assume treatment 1 (TX1) is the standard treatment and treatment 2 (TX2) is a new targeted agent. All patients are evaluated for their marker status (À or þ) before randomization. We assume that there are no measurement errors in marker status, and the outcome is binary and the result can be observed quickly. Scenario 1 shows the null case in which regardless of the patients' marker status or the treatment assignment, the response rate (p) is 0.2 in all cases. Scenario 2 shows that the marker is prognostic, where p ¼ 0.4 in Mþ patients, which is better than p ¼ 0.2 in MÀ patients regardless of treatments. On the other hand, scenario 3 shows the case where there is a treatment effect but no marker effect. Scenario 4 gives an example that the marker is predictive but not prognostic. The new treatment does not work in MÀ patients (p ¼ 0.2) but works very well in Mþ patients (p ¼ 0.6). Lastly, scenario 5 shows the case where the marker is both prognostic and predictive. Comparing to the standard treatment, the new treatment works slightly better in the MÀ patients but much better in Mþ patients (p ¼ 0.2 vs. 0.1 and 0.6 vs. 0.3, respectively).
Several designs have been proposed in the literature for evaluating targeted agent in this setting. We compare the operating characteristics of five recently proposed designs, namely, the simple randomization design, the marker stratified design, the marker strategy design [28] , the efficient targeted design [24, 25] and the BAR design. The schematic diagram of these designs is given in Figure 2 . In the simple randomization design, patients are randomized equally into the standard or the targeted treatment without the knowledge of the marker status. Simple randomization design can be used to test the overall treatment effect in the whole patient population. Conditional on the post hoc analysis by patients' marker status, it can also be used to test treatment effect in the MÀ and Mþ patients separately. However, the marker distribution may not be balanced between the two treatment groups for small samples. If markers are measured retrospectively, a higher missing rate could occur. On the other hand, the marker stratified design requires that marker values be obtained at baseline. Upon stratifying on marker status, patients are equally randomized into the standard and targeted treatments. The prognostic effect of the marker can be tested by comparing A versus C. Testing A versus B or C versus D can be used to assess the treatment effects in patients within each marker group. The predictive effect can be tested by comparing the odds of treatment response between MÀ and Mþ patients (A/B vs. C/D). In the marker strategy design, patients are first randomized between strategies. Patients randomized into the nonstrategy arm either receive the standard treatment or can be randomized equally to the standard and targeted treatments. The latter design is used for comparing with other designs. For patients randomized into the marker strategy arm, the treatment assignment is deterministic. MÀ patients receive standard treatment, whereas Mþ patients receive targeted treatment. The differential effect of the two strategies can be compared by testing A þ B versus C þ D. The comparison between A and B can test the treatment effect in the unselected population. Similarly, the treatment effect in the selected population can be tested by the comparison between C and D. Efficient targeted design is an enrichment design that only treats Mþ patients in the trial. MÀ patients are treated off protocol. 
It can answer the question whether targeted treatment works in the Mþ patients, but its effectiveness in MÀ patients cannot be assessed. BAR design is a model-based approach, where the treatment effects are evaluated in marker groups progressively. The design structure is similar to marker stratified design, where randomization is conducted conditionally on marker status. However, instead of using ER, covariate-adjusted AR by marker is applied to allocate more patients to the putatively superior treatment.
With two marker groups and two treatments, logistic regression can be applied to test for the marker effect, the treatment effect, and their interaction. The model can be formulated as follows. For patient i, we assume:
where Y i is the response indicator, i is the probability of response, M i is the marker indicator, and T i is the treatment indicator. For the BAR design, we assume that the parameters follow a multivariate normal distribution with a non-informative (NI) prior. Simulation studies are performed to evaluate the operating characteristics of the above designs. Randm.
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A We run 5000 simulations for the frequentist designs and 1000 simulations for the Bayesian design. We assume that the total sample size is 150 and the Mþ probability of 0.5. Table 3 gives the statistical power for testing the marker effect, the treatment effect, and the marker by treatment interaction (i.e., whether the marker is predictive). For the marker strategy design, because patients' marker status is assumed to be available, we carry out the post hoc logistic regression analysis to test for the above effects. In addition, we report the results of testing whether the treatment works in patients randomized into nonstrategy and strategy approaches, and the power for comparing the two strategies. The last column shows the averaged overall response rate in all patients enrolled in the trial. All the frequentist tests are carried out at a two-sided 5% significance level.
For the BAR design, we let the first 50 patients to be equally randomized, so we can obtain initial estimates of the parameters. Starting from the 51st patient, patients are randomized to treatment 1 with probabilityp 1 =ðp 1 þp 2 Þ, wherep i is the current estimate of the response rate in treatment i, i ¼ 1, 2. At the end of study, a parameter is considered significantly different from 0 if Pr( > 0) >, where represents for T in testing treatment effect in MÀ patients, for T þ I in testing treatment effect in Mþ patients, for M in testing marker effect in TX1, and for M þ I in testing marker effect in TX2. An overall treatment effect is defined as TX2 is better than TX1 in either MÀ or Mþ patients or in the whole group. Similar definition is applied for the overall marker effect. The cutoff is selected to correspond to 5% type I error rate under the null hypothesis.
In scenario 1, when there is no marker effect or treatment effect, the statistical power (type I error) is between 0 and 0.06 in all settings. The overall response rate is indeed 0.2 in all settings. In our case with the Mþ proportion being 0.5, the performance of the simple randomization design and the marker stratified design (both are ER designs) is essentially identical.
For scenario 2, ER design shows the power for testing the marker effect is about 46% in each treatment subgroups and about 71% in all patients. Due to the imbalanced allocation in the marker strategy design (approximately 37.5% in the MÀ, TX1 and Mþ, TX2; and 12.5% in MÀ, TX2 and Mþ, TX1), the corresponding powers are reduced. Because there is no treatment effect, the powers for testing the treatment effect are around the levels of type I error rates in the null case in all designs.
In scenario 3, when there is a treatment effect but no marker effect, all designs show the power for testing the marker effect is hovering around the 5% type I error rate. The power for testing the overall treatment effect is higher in the ER design (about 71%) than the marker strategy design (54%) as shown earlier. The power for testing the treatment effect using the efficient targeted design is only 47% because it screens out the MÀ patients. In scenario 4, when marker is predictive but not prognostic, the type I errors for testing the marker's prognostic effect and the treatment effect in MÀ patients are all less than 5% for all designs. The powers for testing the marker effect in TX2 patients or treatment effect in Mþ patients are greater than 90% for the ER design and the efficient targeted design but in the mid-80% range for the marker strategy design. The power for testing the marker's predictive effect (i.e., marker by treatment interaction) is about 63% for the ER designs and only 46% for the marker strategy design.
In scenario 5, when the marker is both prognostic and predictive, the powers for testing the marker effect and the treatment effect are all greater than the nominal significance level. The performance of the efficient targeted design is similar to the ER designs and is better than the marker strategy design.
For the marker strategy design, we also evaluate the treatment effect in patients assigned to nonstrategy arm, strategy arm, and the power for comparing strategy versus nonstrategy arm. For scenario 2, the power for testing the treatment effect in patients assigned to the strategy approach arm is 46%. This means that taking the marker strategy approach, there is evidence showing that patients assigned to the targeted agent fare better than patients assigned to the standard treatment. Hence, it may lead to an erroneous conclusion that the targeted agent works better than the standard treatment. The difference is, in fact, due to the marker effect and not the treatment effect. The strategy approach leads to a total confounding between marker and treatment. Hence, when difference is observed, it is not known whether it is attributed to the marker or the treatment. Another important observation is that, for the marker strategy design, the power for testing strategy versus no-strategy approaches is consistently low in all scenarios. Even in scenarios 4 and 5, when the marker is predictive, the powers are only 25% and 10%, respectively. The low power is a result of a significant overlap in treatment assignments between the two.
For the BAR design, we choose the cutoff value ¼ 0.983 to control the type I error rate to 0.05. For scenario 2, the powers of the BAR design for testing the marker effect are comparable to the ER design. For scenario 3, the power of the BAR design for testing the treatment effect is slightly lower than the ER design (62% vs 70% for testing overall treatment effect). Due to AR, the slight loss of power can also be seen in scenarios 4 and 5 (87% vs 95% and 71% vs 79%, respectively).
We also compare the overall response rate in all designs. For scenario 2, efficient targeted design has 40% response rate because only Mþ patients are enrolled. In scenario 3, BAR gave the best result with a response rate of 34%. For scenario 4, efficient targeted design yields a response rate of 40%, while the marker strategy design and BAR give a response rate of 35%. Likewise, in scenario 5, efficient targeted design has the highest overall response rate (45%), followed by BAR (34%), marker strategy design (33%), and ER (30%). ER design has the lowest response rate in all scenarios.
BAR applied in designs with multiple treatments and multiple markers
BAR design can be applied to settings when multiple markers are involved in evaluating the effect of multiple treatments. To illustrate its use, we give an example when two markers are used for evaluating four treatments. Specifically, we recently designed a biomarker-based clinical trial in advanced-staged lung cancer patients. Building upon a similar trial called BATTLE (Biomarker-Integrated Approaches of Targeted Therapy of Lung Cancer Elimination) [28] , our BATTLE-2 trial is to test four treatments with multiple biomarkers. The primary endpoint is the 8week disease control rate (DCR) defined as patients without progression by the end of 8 weeks after randomization [29] . The trial was designed with a total sample size of 320 in two stages (160 patients per stage). There are four treatments, namely, erlotinib, erlotinib þ an AKT inhibitor, erlotinib þ an IGFR inhibitor, and an AKT inhibitor þ a MEK inhibitor. In stage 1, two well established markers (EGFR mutation and K-ras mutation) are used to guide the patient allocation. Patients will be adaptively randomized in stage 1 based on the two markers. From stage 1, more putative and discovery markers are identified to refine the predictive model, which will then be used in adaptively randomizing patients in stage 2.
We use only the stage 1 part to illustrate how BAR can be applied in this setting. The design has one more complication: two types of patients are recruited -erlotinib-naïve who have not been exposed with erlotinib and erlotinib-resistant who had prior erlotinib treatment but failed. Per design, erlotinib-naïve patients can be randomized in any one of the four treatments, but erlotinib-resistant patients is excluded from erlotinib only treatment, and can only be randomized into one of the three combination treatments.
The statistical model is given below. Let X i be a n Â q design matrix, n is the total number of patients, q is the total number of parameter including intercept, J is the total number of treatments, and K is the total number of markers. Under the framework of the logistic model, the DCR p i for the ith patient can be expressed as follows:
where T ij is the indicator for the experimental treatments (TX2, TX3, or TX4), M ik is the indicator for positive marker status, and Z i is the indicator for erlotinib-resistant patient. For erlotinib-naïve patients, the probability of patient being assigned to the jth treatment is proportional to Prð p j >p j 0 , j 0 2 f1, 2, 3, 4j j 0 6 ¼ jgÞ. For erlotinibresistant patients, allocation to TX1 is prohibited, and the probability of patient being assigned to TX2, TX3, or TX4 is proportional to Prð p j >p j 0 , j 0 2 f2, 3, 4j j 0 6 ¼ jgÞ.
Our main interest is to test for the effect of new treatments (TX2, TX3, TX4) versus the standard treatment (TX1) in the following settings.
(1) Evaluation of the marginal treatment effect in all patients
The marginal treatment effect will be tested using model (3) with only treatment and marker main effect present:
Experimental treatment, TX j (j ¼ 2, 3, 4) will be claimed as having a significant marginal treatment effect in all patients if Pr( j > 0) > , where is the threshold cutoff value for posterior inference. That is, we call the experimental treatment better than the standard if the probability of the DCR in the experimental treatment being greater than the DCR in the standard treatment is greater than .
(2) Evaluation of the marginal treatment effect in erlotinib-resistant and in erlotinib-naïve patients
The marginal treatment effect in the erlotinibresistant and in the erlotinib-naïve patients will be tested using model (4) , which include Z i :
TX j (j ¼ 2, 3, 4) will be claimed as having a significant marginal treatment effect in naïve patients if Pr( j > 0) > and in resistant patients if Prð j þ 0 j >0Þ>.
(3) Evaluation of the treatment effects in erlotinibresistant and in erlotinib-naïve patients in different marker groups
It is assumed that, among erlotinib-naïve patients, M1þ patients will have a better response to the experimental treatments than M1À patients. If there are no marginal treatment effects in either the overall patient population or erlotinib-naïve or erlotinib-resistant patients, we will further evaluate the treatment effect in erlotinib-naive patients expressing particular markers using the full model in Equation (2). Experimental treatment j (j ¼ 2, 3, 4) will be claimed as having a significant treatment effect in erlotinib-naïve and marker k positive patients if Pr( j þ kj > 0) > and in erlotinibresistant and marker k positive patients if Prð j þ kj þ 0 j þ 0 kj >0Þ>. Simulations are conducted with 2000 runs for each scenario to evaluate the operating characteristics. For each run, a total of 5000 Markov chain Monte Carlo iterations after 5000 burn-in draws are used to make posterior inferences. We assume 44% of the 160 patients are erlotinib resistant and the remaining 56% are erlotinib-naïve based on our prior data. We also assume that the EGFR mutation rate and K-ras mutation rate are both at 20%, and they are independent to each other. Two priors were used to evaluate the operating characteristics: (1) a NI independent normal (0, 100) prior is used for all parameters; (2) same as in (1) but an informative beta prior for the erlotinib only treatment in the erlotinib-resistant patients. Because no erlotinib-resistant patients are assigned to the erlotinib only arm, when testing the treatment efficacy in resistant patients with the NI prior option, the inference is essentially based on comparing the treatment effects of experimental arms to a very diffuse prior centered at 0.5, which could yield a very low power. Therefore, the use of a NI prior may not be reasonable. The very reason that we do not assign erlotinib-resistant patients into the erlotinib only arm is because the treatment does not work in this setting. Sim et al. [30] reported data from 16 patients who were treated with gefitinib first, followed by erlotinib upon gefitinib failure. The DCR was 69% in the gefitinib treatment and 25% in the subsequent erlotinib treatment. We implement this information through our second prior option, the beta prior. To discount the weight of the historical data, we assume that the DCRs for the erlotinib treatment in the erlotinib-resistant patients follow beta prior distributions with an effective sample size of 5. The order of magnitude of treatment effect in the literature is similar to the ones shown in Table 4 .
The total numbers of patients randomized into each marker by treatment combinations are given in Table 5 . Under the null hypothesis, the numbers of patients treated in each arm are very similar to each other as expected. Under the alternative hypothesis, for naïve patients, the numbers of patients in the erlotinib arm is smaller than the combination arms because the combination arms have higher DCRs. Table 6 shows the statistical power for testing the treatment effect under various settings. An overall treatment effect is defined as significant if the effect is shown in either marginal effect (for all patients or for subgroup of patients) or in any marker-positive patients. If any of TX 2, 3, and 4 have significant effect, the trial will be claimed as a success. For the Bayesian design, a cutoff value is chosen to declare the test result being 'significant'. We chose such that the type I error rate under the null hypothesis for testing treatment effect of experimental arm versus erlotinib only arm is 10%. For NI prior, ¼ 0.982, and for the beta prior, ¼ 0.984.
With the NI prior, the powers for testing TX 2, 3, and 4 being better than TX1 are 0.632, 0.592, and 0.622, respectively. The power gains are mainly from the erlotinib-naïve patients as it is evident that the power gain from the erlotinib-resistant patients is essentially nil. This is due to the nature of the NI prior and no resistant patients are assigned to the erlotinib only arm to update information. In contrast, even with a weak informative beta prior (with an effective sample size of 5), we gain power for testing the treatment effect in the resistant patients. The power for testing TX 2, 3, and 4 being effective increased to 0.787, 0.861, and 0.801, respectively. The overall family-wise type I error rate is 0.184 and 0.174 for the NI and beta prior, respectively. The corresponding overall power is 0.865 and 0.987. To compare the performance of the Bayesian design with frequentist's design, Table 7 shows the corresponding statistical power using the Fisher's exact test. Because there is no data in the erlotinibresistant group treated with erlotinib, we show the results based on the whole group (margin) and for the naïve patients only. Fisher's exact test is chosen because the maximum likelihood estimators from logistic regressions often failed due to the small sample size and no events in biomarker subgroups. The overall power is 0.923, which is higher than the Bayesian design with a NI prior but lower than the Bayesian design with an informative prior.
Discussion
For developing targeted agents, it is indeed challenging to ask for a design that is accurate, efficient, ethical, and flexible. Through simulation studies, we have compared the performance of various frequentist designs and the BAR design. For the frequentist designs, simple randomization design and marker stratified design have similar operating characteristics, but the marker stratified design can ensure that treatments are equally assigned in each marker group, and the prospective evaluation of markers can improve the completeness and accuracy of the marker data. Efficient targeted design only tests the treatment efficacy in selected marker group(s); hence, it reduces the trial sample size. It is most efficient when there is sufficient evidence that the treatment is most likely to work only in the selected marker groups and unlikely to work in the other groups. However, in most settings, the answers to these questions remain unknown. This is exactly the reason why we need to conduct clinical trials in the first place. Although the efficient targeted design can test the treatment effect in the selected group, the effect in other marker groups cannot be assessed. Marker strategy design may sound like a reasonable approach, but due to the Table 6 Statistical power for testing the treatment effect under the null and alternative hypotheses for erlotinib-resistant and -naïve patients by marker status in the BATTLE-2 adaptive randomization design using the Bayesian logistic regression confounding between the marker effect and the treatment effect, the design cannot accurately attribute the difference in outcomes to marker, treatment, or their combinations. The design also has very little power in comparing the strategy versus nonstrategy approaches. BAR design allocates more patients in more effective treatments as the trial progresses and information accumulates. It continues to learn about the effects of markers, treatments, and their interactions along the trial and adjusts the randomization proportion accordingly. By carefully calibrating the design parameters, types I and II errors can be controlled for the Bayesian designs. AR can result in mild loss in statistical power due to imbalance allocation between treatment groups. It, however, gains efficiency through modeling and the appropriate use of the prior information. Larger sample size in more effective treatments can also result in higher precision in estimating the corresponding treatment effects. Furthermore, adding futility or efficacy early stopping rules can reduce the sample size. Although the BAR designs yield only incremental improvements over the frequentist's counterparts, Bayesian approach provides a uniform way of setting up complex problems, parameter estimation, and inference making. Bayesian framework also allows more flexible study conduct, such as dropping ineffective treatments and adding new treatments, because the inference is based on the data (conformed with the likelihood principle) and does not depend on a fixed sampling plan.
The validity of the Bayesian models that we have discussed, however, depends on the proper model specification and the assumed parameters. Extensive simulations should be conducted to evaluate the operating characteristics of the design under various settings. A conservative approach should be taken in choosing the sample size and in controlling type I errors. Highly complex models may gain efficiency but lack robustness. Model checking and sensitivity analysis are required to ensure that the model provides adequate fit for the data.
Early phase of drug developing is about discovery and learning. Adaptive design provides an ideal platform for learning and enables the investigators to continue to learn about the new agents' clinical activities during the trial and apply this knowledge to better treat patients in real time. It can increase the study efficiency, allow flexibility in study conduct, and provide better treatment to study participants, which is a step toward personalized medicine.
One limitation of the response-based AR is that it requires the response to be assessed in a relatively short time period. Infrastructure setup is necessary to allow more frequent monitoring of interim results. Extra steps need to be taken to ensure the integrity of the study conduct, for example, timely and objective evaluation of endpoints. Due to the large number of tests, the overall false positive rate may increase. Results found in one trial need to be confirmed in other trials, which includes the validation of both the predictive markers and the treatment efficacy. Upon the identification of efficacious treatments and corresponding markers, a more focused confirmatory trial can be designed accordingly.
The success of Bayesian adaptive trials requires an integrated multidisciplinary research team of clinical investigators, who see patients and perform biopsies, basic scientists who run the biomarker analysis, computer programmers who build Webbased database applications, and statisticians who provide the design and implementation of AR.
In summary, Bayesian designs can be more ethical and efficient by incorporating AR and early stopping rules. The proposed new designs incorporate rational learning from the interim data for randomization and making decisions on treatment efficacy. BAR designs are distinctively suitable for the development of multiple targeted agents with multiple biomarkers. Although it requires more efforts on trial design, simulation, setting up the infrastructure, trial conduct, analysis, and reporting, Bayesian designs have gain increasing popularity recently and have been implemented in many settings [23, 28] . In reviewing papers demonstrating that Bayesian clinical trials are currently in action, Gonen has aptly titled his editorial 'Bayesian clinical trials: no more excuses' [31] .
